Frail elderly patients with relapsed-refractory multiple myeloma: Efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 937-940

  Mele, Giuseppe ^a   Giannotta, Angela ^a   Pinna, Salvatore ^a   Loseto, Giacomo ^a   Coppi, Maria Rosaria ^a   Brocca, Claudio Maurizio ^a   Melpignano, Angela ^a   Quarta, Giovanni ^a  

^a 'Antonio Perrino' Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; BORTEZOMIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN;

AGED; BRONCHOPNEUMONIA; CANCER RELAPSE; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; EVENT FREE SURVIVAL; FEMALE; FRAIL ELDERLY; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; LEG EDEMA; LETTER; LOW DRUG DOSE; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PRIORITY JOURNAL; REFRACTORY PERIOD; SYNCOPE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; FRAIL ELDERLY; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77951810926     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003695660     Document Type: Letter

References (12)

1. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: update results of a randomized controlled trial. Blood 2008;112:3107-3114.
2. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trial. Lancet 2007;370:1209-1218.
3. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide patients older than 75 years with newly diagnosed multiple myeloma: IFM01/01 trial. J Clin Oncol 2009;27:3664-3670.
4. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224-237.
5. de Weerdt O, van de Donk NW, Veth G, et al. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001;59:50-56.
6. Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578-1582.
7. Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood 2005; 106 (Suppl. 1) : 716a (Abstract 2549).
8. Richardson PGG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977-2981.
9. San Mighel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
10. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-762.
11. Reece DE, Piza Rodriguez G, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777-4783.
12. Durie Brian GM, Salmon Sydney E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-854.